A Randomized Double-Blind Placebo-Controlled Clinical Trial of Adjuvant Buspirone for Irritability in Autism

Ghanizadeh, Ahmad; Ayoobzadehshirazi, Anaheed

doi:10.1016/j.pediatrneurol.2014.09.017

Cited by 41 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Buspirone was hypothesized to play a role in irritability associated with ASD by boosting serotonin levels in the brain . The theory is supported clinically in one randomized double‐blind placebo‐controlled trial of buspirone (10 mg/day in patients less than 40 kg or 20 mg/day in patients more than 40 kg) as an adjunct to risperidone (2 mg/day in patients less than 40 kg or 3 mg/day for patients more than 40 kg) in 40 children and adolescents with ASD.…”

Section: Review Of Available Data: Dual Therapymentioning

confidence: 98%

“…The theory is supported clinically in one randomized double‐blind placebo‐controlled trial of buspirone (10 mg/day in patients less than 40 kg or 20 mg/day in patients more than 40 kg) as an adjunct to risperidone (2 mg/day in patients less than 40 kg or 3 mg/day for patients more than 40 kg) in 40 children and adolescents with ASD. During the 8‐week study duration, 81.2% of patients in the buspirone group compared with 38.9% of patients in the placebo group had a 30% or greater decline in irritability score . The most common side effects observed in the buspirone group were increased appetite, drowsiness, and fatigue.…”

Section: Review Of Available Data: Dual Therapymentioning

confidence: 99%

See 1 more Smart Citation

Management of Self‐injurious Behaviors in Children with Neurodevelopmental Disorders: A Pharmacotherapy Overview

et al. 2019

View full text Add to dashboard Cite

Neurodevelopmental disorders (NDDs), a group of disorders affecting ~1–2% of the general population, are caused by changes in brain development that result in behavioral and cognitive alterations, sensory and motor changes, and speech and language deficits. Neurodevelopmental disorders encompass a heterogeneous group of disorders including, but not limited to, Smith‐Magenis syndrome, Lesch‐Nyhan disease, cri du chat syndrome, Prader‐Willi syndrome, pervasive developmental disorders, fragile X syndrome, Rett syndrome, Cornelia de Lange syndrome, and Down syndrome. Self‐injurious behaviors (SIBs) are common in children with NDDs; depending on the specific NDD, the incidence of SIBs is nearly 100%. The management of SIBs in this population is complex, and little high‐quality data exist to guide a consistent approach to therapy. However, managing SIBs is of the utmost importance for the child as well as the family and caregivers. Behavior therapies must be implemented as first‐line therapy. If behavioral interventions alone fail, pharmacotherapy becomes an essential part of management plans. The limited available evidence for the use of common pharmacologic agents, such as second‐generation antipsychotics, and less common agents, such as clonidine, n‐acetylcysteine, riluzole, naltrexone, and topical anesthetics, is reviewed. Additional data from well‐designed studies in children with NDDs are needed to gain a better understanding of this common and troublesome problem including efficacy and safety implications associated with pharmacotherapy. Until then, clinicians must rely on the limited available data, clinical expertise, and ongoing systematic monitoring when managing SIBs in children with NDDs.

show abstract

Section: Review Of Available Data: Dual Therapymentioning

confidence: 98%

Section: Review Of Available Data: Dual Therapymentioning

confidence: 99%

Management of Self‐injurious Behaviors in Children with Neurodevelopmental Disorders: A Pharmacotherapy Overview

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Thirteen studies met inclusion criteria for targeting irritability/agitation in ASD (Table a‐b), including two psychosocial and 11 pharmacological interventions .…”

Section: Results and Clinical Practice Recommendationsmentioning

confidence: 99%

“…Of the 11 pharmacological trials evaluated, nine small single trials with low risk of bias investigated combined treatment with risperidone plus a second agent over risperidone alone, using the ABC‐I as primary endpoint (see Table a‐b). Single study data for a wide range of drug classes were investigated with significant small to large effects favouring combined treatment over risperidone alone.…”

Section: Results and Clinical Practice Recommendationsmentioning

confidence: 99%

Systematic review and guide to management of core and psychiatric symptoms in youth with autism

Ameis

Kassee

Corbett-Dick

et al. 2018

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…Buspirone [95,[201][202][203], fluoxetine [204][205][206][207][208], escitalopram [209,210], citalopram [211], sertraline [212][213][214], D cycloserine [186,[215][216][217][218], amantadine [219], and memantine [220][221][222] have already been used in clinical research into autism. Finally, naltrexone, a potent opiate antagonist tested in ASD for improving behavioral changes [223][224][225][226][227][228][229][230][231][232][233][234][235][236][237][238][239], could also possess immunomodulatory action [240].…”

Section: Discussionmentioning

confidence: 99%

Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy

Marchezan

Santos

Deckmann

et al. 2018

Neuroimmunomodulation

View full text Add to dashboard Cite

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with an unknown etiology and currently few effective therapies. Immune system alterations have being demonstrated in ASD, both in humans and via animal models; immune imbalance thus arises as a possible pathway for drug intervention. In this review, the studies were classified into 2 major groups: (1) clinical research whose authors classify therapies with primary anti-inflammatory and immunomodulatory actions, making use of: sulforaphane, celecoxib, lenalidomide, pentoxifylline, spironolactone, flavonoid luteolin, corticosteroids, oral immunoglobulin, intravenous immunoglobulin, cell therapy, dialyzable lymphocyte extracts, minocycline, and pioglitazone; and (2) other ASD therapies already used or currently under study whose initial characteristics were neither anti-inflammatory nor immunomodulatory initially, but displayed a capacity for immunomodulation throughout the treatment: risperidone, vitamin D, omega-3, Ginkgo biloba, L-carnosine, N-acetylcysteine, and microbiome restoration. These studies used various data acquisition methodologies. Questions arose such the need for randomized and placebo-controlled studies with greater numbers of participants as well as the use of biomarkers to refine the treatment of autistic subjects.

show abstract

A Randomized Double-Blind Placebo-Controlled Clinical Trial of Adjuvant Buspirone for Irritability in Autism

Cited by 41 publications

References 25 publications

Management of Self‐injurious Behaviors in Children with Neurodevelopmental Disorders: A Pharmacotherapy Overview

Management of Self‐injurious Behaviors in Children with Neurodevelopmental Disorders: A Pharmacotherapy Overview

Systematic review and guide to management of core and psychiatric symptoms in youth with autism

Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy

Contact Info

Product

Resources

About